dsm-firmenich reports good H1 2026 results
The company posted 5% LFL sales growth and sequential margin improvement, with an unchanged outlook for 2026.
See the latest news and media coverage for dsm-firmenich. We track all announcements, press releases, and industry mentions in real time, all in one place.
Nutrition, health, and beauty innovation company
dsm-firmenich.comLast updated
In short: dsm-firmenich posted H1 sales growth, cut 1,000 jobs, and won FDA approval for PARSOL Shield sunscreen.
The company posted 5% LFL sales growth and sequential margin improvement, with an unchanged outlook for 2026.
The dual listing strengthens capital markets presence in Switzerland and broadens access to Swiss institutional investors.
Key approvals include board re-elections, €2.50 dividend, and remuneration for board and executive committee. Meeting held May 7, 2026.
Achieves 4% LFL sales growth and maintains FY 2026 outlook. Introduces 2026-2028 action plan, announces Swiss listing, and €500M share buyback.
DSM-Firmenich AG (DSFIR.AS, DSFIY) on Thursday said that its net attributable profit declined in the first half of fiscal 2026. Like-for-like sales, however, rose 5...
Shares in DSM-Firmenich climbed after like-for-like sales accelerated in the second quarter and growth outperformed analyst expectations. The Dutch ingredients supplier booked 2.39 billion euros...
Dsm-firmenich on Thursday beat market expectations for second-quarter core earnings and said full-ye...
European chemicals maker dsm-firmenich on Wednesday reported adjusted first-quarter core profit in line with market expectations, driven by strong demand for its perfumery & beauty...
Track dsm-firmenich and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to dsm-firmenich and other trending companies.